Cutler Group’s NRX Pharmaceuticals NRXP Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2024
Q1
$1K Hold
322
﹤0.01% 2069
2023
Q4
$1K Hold
322
﹤0.01% 3379
2023
Q3
$0 Hold
322
﹤0.01% 4160
2023
Q2
$1K Hold
322
﹤0.01% 3353
2023
Q1
$2K Hold
322
﹤0.01% 3204
2022
Q4
$3K Hold
322
﹤0.01% 3511
2022
Q3
$2K Hold
322
﹤0.01% 4254
2022
Q2
$1K Hold
322
﹤0.01% 4664
2022
Q1
$7K Sell
322
-380
-54% -$12.4K ﹤0.01% 3899
2021
Q4
$33K Sell
702
-43
-6% -$3.1K ﹤0.01% 2726
2021
Q3
$69K Buy
+745
New +$96.9K ﹤0.01% 2231

Other funds holding NRXP

Cutler Group's NRXP Position: Q1 2024 in Review

Cutler Group held its NRX Pharmaceuticals (NRXP) position steady in Q1 2024 at 322 shares worth $1K. The position accounts for ﹤0.01% of the portfolio, ranked #2069.

Cutler Group first reported a position in NRXP in Q3 2021 and has held it in 11 quarters since. The position peaked at $69K in Q3 2021. 31 funds tracked by Wall St. Rank hold NRXP as of Q1 2024.

  • Cutler Group held 322 shares of NRX Pharmaceuticals worth $1K as of Q1 2024.
  • Cutler Group left its NRX Pharmaceuticals share count unchanged in Q1 2024.
  • NRX Pharmaceuticals made up ﹤0.01% of Cutler Group's portfolio in Q1 2024, its #2069 holding.
  • Cutler Group first reported a position in NRX Pharmaceuticals in Q3 2021 and has held it in 11 quarters since.
  • Cutler Group's NRX Pharmaceuticals position peaked at $69K in Q3 2021.
  • 31 funds tracked by Wall St. Rank held NRX Pharmaceuticals as of Q1 2024.

Based on Cutler Group's 13F filing for Q1 2024, filed 19 Apr 2024.